Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection - PubMed (original) (raw)
Clinical Trial
Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection
Ellen S Engelson et al. J Acquir Immune Defic Syndr. 2002.
Abstract
HIV-associated lipodystrophy often includes excess accumulation of visceral fat. Recombinant human growth hormone (rhGH) is a potential treatment for the excess visceral fat. Prospective, open-label trials of 24 weeks of rhGH 6 mg/d and 24 weeks of 4 mg every other day were conducted with an intervening washout period of 12 weeks. Thirty HIV-positive participants (26 men and 4 women) with visceral adiposity were enrolled. The main outcome measure was change in visceral adipose tissue (VAT) on whole-body magnetic resonance imaging scan. Changes in whole-body subcutaneous adipose tissue and skeletal muscle, glucose metabolism, serum lipids, and quality of life were also assessed. Despite stable body weight, VAT decreased in evaluable subjects an average of 42% with rhGH 6 mg/d (n = 24; p <.001) and 15% with 4 mg every other day (n = 10; p <.01) after 12 weeks, with trends toward further decreases after an additional 12 weeks at each dose. Subcutaneous adipose tissue also decreased, but proportionately less and not significantly on the lower dose. Skeletal muscle increased. Body composition rebounded to or near baseline after the washout period. Effects on lipids were inconsistent. Total cholesterol levels fell on the higher dose only, whereas high-density lipoprotein cholesterol levels increased on the lower dose only, and there was no effect on triglyceride levels. Joint pain was the most common adverse event, and was reflected in subjective quality of life measurements as an increase in bodily pain. Insulin sensitivity fell, and 4 participants developed diabetes. Other adverse events included cancer of unknown relationship to treatment in 3 participants. Levels of distress decreased after 24 weeks on the higher dose. In conclusion, rhGH effectively reduces the excess visceral adipose tissue often associated with HIV fat redistribution/lipodystrophy. However, frequent adverse effects warrant controlled studies and careful patient monitoring, especially regarding glucose tolerance.
Similar articles
- Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
Viganò A, Mora S, Manzoni P, Schneider L, Beretta S, Molinaro M, di Natale B, Brambilla P. Viganò A, et al. J Clin Endocrinol Metab. 2005 Jul;90(7):4075-80. doi: 10.1210/jc.2004-2431. Epub 2005 Apr 19. J Clin Endocrinol Metab. 2005. PMID: 15840750 - Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Falutz J, et al. N Engl J Med. 2007 Dec 6;357(23):2359-70. doi: 10.1056/NEJMoa072375. N Engl J Med. 2007. PMID: 18057338 Clinical Trial. - Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
Hansen BR, Haugaard SB, Jensen FK, Jensen JE, Andresen L, Iversen J, Andersen O. Hansen BR, et al. HIV Med. 2010 Apr;11(4):266-75. doi: 10.1111/j.1468-1293.2009.00775.x. Epub 2009 Dec 8. HIV Med. 2010. PMID: 20002779 Clinical Trial. - Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
Sivakumar T, Mechanic O, Fehmie DA, Paul B. Sivakumar T, et al. HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111/j.1468-1293.2010.00906.x. Epub 2011 Jan 25. HIV Med. 2011. PMID: 21265979 Review. - Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.
Benedini S, Terruzzi I, Lazzarin A, Luzi L. Benedini S, et al. BioDrugs. 2008;22(2):101-12. doi: 10.2165/00063030-200822020-00003. BioDrugs. 2008. PMID: 18345707 Review.
Cited by
- The acromegaly lipodystrophy.
Freda PU. Freda PU. Front Endocrinol (Lausanne). 2022 Sep 13;13:933039. doi: 10.3389/fendo.2022.933039. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36176462 Free PMC article. - Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
Clemmons DR, Miller S, Mamputu JC. Clemmons DR, et al. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. eCollection 2017. PLoS One. 2017. PMID: 28617838 Free PMC article. Clinical Trial. - The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity.
Lewitt MS. Lewitt MS. Biochem Insights. 2017 Apr 20;10:1178626417703995. doi: 10.1177/1178626417703995. eCollection 2017. Biochem Insights. 2017. PMID: 28469442 Free PMC article. Review. - Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.
Tien PC. Tien PC. Curr Atheroscler Rep. 2015 Dec;17(12):73. doi: 10.1007/s11883-015-0545-2. Curr Atheroscler Rep. 2015. PMID: 26493063 Review. - The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.
Kotler DP, He Q, Engelson ES, Albu JB, Glesby MJ. Kotler DP, et al. Antivir Ther. 2016;21(2):107-16. doi: 10.3851/IMP2927. Epub 2014 Dec 23. Antivir Ther. 2016. PMID: 25536669 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical